Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Perrigo Eyes $115 Billion In Rx-To-OTC Switches On The Horizon

Nov 28 2012

• By Dan Schiff

Related Content

Sales & Earnings In Brief

Oct 31 2011

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture

Oct 03 2011

<em>Nexium</em> OTC Switch Would Face Crowded Field, Potential Questions

Aug 20 2012

<em>Oxytrol</em> Switch Should Hinge On Symptom ID, Not Diagnosis – Merck Consultant

Nov 19 2012

Perrigo Nutritional Dip Riles Analysts Amid Record Consumer Sales

Nov 12 2012

Statin Label Change Stirs OTC Switch Discussions

Mar 05 2012

Related Companies

Perrigo Company PLC

Pfizer Inc.

Merck & Co., Inc.

AstraZeneca PLC

Eisai Co., Ltd.

Additional Topics

United States Business Strategies Launches Advertising, Marketing & Sales Manufacturing Prescription To OTC Switch Regulation OTC Drugs Consumer BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window